We forward to you today a number of items of possible interest:
National Credit Union Administration issues guidance to assist legal hemp industry: The National Credit Union Administration (NCUA) issued guidance about changes in federal law related to hemp for federally insured credit unions interested in providing financial services to the legal hemp industry. https://www.mcconnell.senate.gov/public/index.cfm
DEA announces steps necessary to improve access to marijuana research: DEA is providing notice of pending applications from entities applying to be registered to manufacture marijuana for researchers. DEA anticipates that registering additional qualified marijuana growers will increase the variety of marijuana available for these purposes. https://www.justice.gov/opa/pr/dea-announces-steps-necessary-improve-access-marijuana-research
Podcast: UNPA's Loren Israelsen on the status of hemp and CBD, in conversation with TraceGains' CEO Gary Nowacki, "CBD: Fad or Trend?" Listen to it at: https://ctoc.podbean.com/e/cbd-fad-or-trend/
Podcast: UNPA's Frank Lampe discusses the state of hemp/CBD regulation in conversation with Pete Thornton of Chatanooga, Tenn.-based Landrace Biosciences, A GMP-certified, bulk CBD product manufacturer. The interview series, geared for the hemp industry, is called, "Call Me Cannabinoids." You can listen to it here.
Hemp, Breeding and genetics: Interesting, well-written article about how "Big Ag" will change the cannabis industry, soon, through plant breeding and genetics: https://mjbizdaily.com/phylos-bioscience-causes-cannabis-industry-disturbance-in-big-ag-video/
Protecting hemp IP: Oregon-based cannabis genomics company Phylos Bioscience’s disclosure that it was positioning itself to be bought by Big Ag underscores the need for marijuana companies to take steps to protect their cannabis genetics and data from falling into the wrong hands. https://mjbizdaily.com/how-cannabis-companies-can-protect-intellectual-property-in-the-wake-of-the-phylos-bioscience-uproar/
UNPA review of CBD comments to FDA: And finally, in case you didn't see it earlier from Kira, access to the Aug. 22 webinar and PPT from UNPA's review and analysis of the formal comments submitted to FDA regarding CBD: PPT and narrative versions attached; listen to the webinar recording by clicking the link.
With warm regards,